FINDINGS:
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax. Post-treatment change: consolidation conforming to beam path.
Mediastinum: Enlarged left hilar lymph node, short axis 1.7 cm. Cardiomediastinal contours within normal limits. no mediastinal mass.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: No focal hepatic lesions. Normal attenuation. no hepatic mass.
Spleen: Normal in size and attenuation. No focal splenic lesion. accessory spleen.
Pancreas: Normal pancreatic contour and enhancement. No focal mass. no pancreatic mass.
Adrenal glands: Adrenal glands are normal without nodules. no adrenal nodule.
Kidneys: No hydronephrosis. No enhancing renal mass. kidneys are normal.
GI tract/Bowel: 5.2 cm lobulated gastric mass at the greater curvature of the stomach (hyperenhancing). No obstructive process. No focal bowel wall mass identified.
Mesentery/Omentum: No ascites. No omental caking.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age.
Lymph nodes: No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture.

IMPRESSION:
- Stomach primary malignancy at greater curvature of the stomach measuring approximately 52 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 52 mm (longest diameter) at baseline.
  • T2: Lymph node — 17 mm (short axis) at baseline.
- SLD baseline: 69 mm.
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: Baseline (no category).
